WHO / IVR / TDR EMVI MVI NIAID

Status, challenges and regulatory strategies to develop a malaria vaccine. Wissenschaftliche Prüfungsarbeit

Status, challenges and regulatory strategies to develop a malaria vaccine Wissenschaftliche Prüfungsarbeit Scientific Thesis zur Erlangung des Titels to obtain the degree Master of Drug Regulatory Affairs

Why use passive immunity?

Vaccines Active vs Passive Immunization Active is longer acting and makes memory and effector cells Passive is shorter acting, no memory and no effector cells Both can be obtained through natural processes:

Recombinant protein vaccines produced in insect cells

Recombinant protein vaccines produced in insect cells Manon M.J. Cox Hong Kong 25JAN2013 Flublok BREAKING NEWS 16JAN2013 FDA approves Flublok for the prevention of influenza in adults 18-49 years old The

Antigenic variation in Plasmodium falciparum : Erythrocyte invasion and immune escape mechanisms

Antigenic variation in Plasmodium falciparum : Erythrocyte invasion and immune escape mechanisms Introduction Why does immunity to malaria take so long to develop? The parasite s survival depends on its

TOWARDS AN HIV VACCINE

why is it so hard to make an HIV vaccine and where are we now? Neal Nathanson, MD Emeritus Professor Department of Microbiology University of Pennsylvania School of Medicine 1 Estimated number of persons

Vaccine Production Strategies: Ensuring Alignment and Sustainability

Vaccine Production Strategies: Ensuring Alignment and Sustainability Second WHO Consultation on Global Action Plan for Influenza Vaccines (GAP-II) Robert W Malone, MD, MS Consulting, Vaccines and Biologicals

CORPORATE PRESENTATION

CORPORATE PRESENTATION At the forefront of innovation in vaccines & monoclonal antibodies April 2012 VIVALIS MODEL A unique positioning in fast growing markets Corporate Overview Vivalis in a snapshot

The immunogenic vaccine against HCV and HBV

National Centre for Research and Development, The immunogenic vaccine against HCV and HBV Katarzyna Grzyb Laboratory of Virus Molecular Biology Intercollegate Faculty of Biotechnology UG-MUG 1 Hepatitis

Anais da Academia Brasileira de Ciências ISSN: 0001-3765 aabc@abc.org.br Academia Brasileira de Ciências Brasil

Anais da Academia Brasileira de Ciências ISSN: 0001-3765 aabc@abc.org.br Academia Brasileira de Ciências Brasil Rodrigues, Mauricio M.; Boscardin, Silvia B.; Vasconcelos, José R.; Salay, Gerson; Soares,

VACCINATIONS FOR ADULT HORSES

VACCINATIONS FOR ADULT HORSES **ALL VACCINATION PROGRAMS SHOULD BE DEVELOPED IN CONSULTATION WITH A LICENSED VETERINARIAN** CORE VACCINATIONS protect against diseases that are endemic to a region, are

Current status of dengue vaccine development

Current status of dengue vaccine development John T. Roehrig, Ph.D. Distinguished Consultant and Research Microbiologist SAGE/Immunization Meeting April 2013 National Center for Emerging and Zoonotic Infectious

Chapter 18: Applications of Immunology

Chapter 18: Applications of Immunology 1. Vaccinations 2. Monoclonal vs Polyclonal Ab 3. Diagnostic Immunology 1. Vaccinations What is Vaccination? A method of inducing artificial immunity by exposing

Treatment and Prevention Options for Clostridium difficile Infection (CDI)

Treatment and Prevention Options for Clostridium difficile Infection (CDI) Dale N. Gerding, MD Professor of Medicine Loyola University Chicago Stritch School of Medicine Research Physician Hines VA Hospital

Antigens & Antibodies II. Polyclonal antibodies vs Monoclonal antibodies

A Brief Review of Antibody Structure A Brief Review of Antibody Structure The basic antibody is a dimer of dimer (2 heavy chain-light chain pairs) composed of repeats of a single structural unit known

VACCINATIONS FOR FOALS

VACCINATIONS FOR FOALS **ALL VACCINATION PROGRAMS SHOULD BE DEVELOPED IN CONSULTATION WITH A LICENSED VETERINARIAN** The two categories below reflect differences in the foal s susceptibility to disease

Identification and localization of minimal MHC-restricted CD8+ T cell epitopes within the Plasmodium falciparum AMA1 protein

RESEARCH Identification and localization of minimal MHC-restricted CD8+ T cell epitopes within the Plasmodium falciparum AMA1 protein Open Access Martha Sedegah 1, Yohan Kim 2, Bjoern Peters 2, Shannon

HuCAL Custom Monoclonal Antibodies

HuCAL Custom Monoclonal Antibodies Highly Specific Monoclonal Antibodies in just 8 Weeks PROVEN, HIGHLY SPECIFIC, HIGH AFFINITY ANTIBODIES IN 8 WEEKS WITHOUT HuCAL PLATINUM IMMUNIZATION (Human Combinatorial

LEADING DENGUE VACCINE CANDIDATE COULD CHANGE THE LIVES OF MILLIONS

FACT SHEET LEADING DENGUE VACCINE CANDIDATE COULD CHANGE THE LIVES OF MILLIONS A GLOBAL PUBLIC HEALTH CHALLENGE Dengue fever, a mosquito-borne disease caused by four types of dengue viruses, is a threat

Vaccines: Poised To Deliver Significant Growth in Emerging Markets Citi Vaccine Seminar Pierre Morgon

March 23, 2011 Vaccines: Poised To Deliver Significant Growth in Emerging Markets Citi Vaccine Seminar Pierre Morgon Vice President, Franchise & Global Marketing Operations Sanofi Pasteur London Forward

Custom Antibodies & Recombinant Proteins

Custom Antibodies & Recombinant Proteins INTRODUCTION Custom services to meet your research and development requirements Improvements in health, medicine and diagnostics over the past century can be largely

Protein Expression. A Practical Approach J. HIGGIN S

Protein Expression A Practical Approach S. J. HIGGIN S B. D. HAMES List of contributors Abbreviations xv Xvi i 1. Protein expression in mammalian cell s Marlies Otter-Nilsson and Tommy Nilsso n 1. Introduction

From Research Services and Process Development to GMP Manufacturing

From Research Services and Process Development to GMP Manufacturing P a r ag o n B i o s e r v i c e s, I n c. A contract research and GMP manufacturing organization (CMO) with a focus on the development

New developments in antigen-specific immunotherapies Novel therapeutic vaccines offer hope in the fight against chronic infectious disease and cancer

New developments in antigen-specific immunotherapies Novel therapeutic vaccines offer hope in the fight against chronic infectious disease and cancer Vaccination has been used effectively for more than

WHO Preferred Product Characteristics (PPC) for Malaria Vaccines

WHO/IVB/14.09 WHO Preferred Product Characteristics (PPC) for Malaria Vaccines DEPARTMENT OF IMMUNIZATION, VACCINES AND BIOLOGICALS Family, Women s and Children s Health (FWC) WHO/IVB/14.09 WHO Preferred

Prospects for Vaccines against Hepatitis C Viruses. T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS

Prospects for Vaccines against Hepatitis C Viruses T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS HCV Vaccine Prevention strategies Protective immunity Barriers and solutions Vaccine candidates

POTENTIAL HAZARD INFORMATION & SIGNATURE SHEET

POTENTIAL HAZARD INFORMATION & SIGNATURE SHEET Scientific research involves exposure to various hazards. When deciding to allow your child to participate in research projects conducted in University of

Accelerating drug development to FTIH: Potential of new expression technologies

Accelerating drug development to FTIH: Potential of new expression technologies Lekan Daramola Associate Director Biopharmaceutical Development, Cell Culture & Fermentation Sciences CMC Strategy Forum

Modelling and analysis of T-cell epitope screening data.

Modelling and analysis of T-cell epitope screening data. Tim Beißbarth 2, Jason A. Tye-Din 1, Gordon K. Smyth 1, Robert P. Anderson 1 and Terence P. Speed 1 1 WEHI, 1G Royal Parade, Parkville, VIC 3050,

CONTENT. Chapter 1 Review of Literature. List of figures. List of tables

Abstract Abbreviations List of figures CONTENT I-VI VII-VIII IX-XII List of tables XIII Chapter 1 Review of Literature 1. Vaccination against intracellular pathogens 1-34 1.1 Role of different immune responses

Therapeutic and Prophylactic AdE1- LMPpoly-Based Adoptive T cell Immunotherapy for Epstein Barr Virus- Associated Nasopharyngeal Carcinoma

Therapeutic and Prophylactic AdE1 LMPpolyBased Adoptive T cell Immunotherapy for Epstein Barr Virus Associated Nasopharyngeal Carcinoma Corey Smith, AACR Meeting, New Orleans, 2016 I have the following

CHAPTER 35 HUMAN IMMUNE SYSTEM STANDARDS:SC.912.L.14.52 & SC.912.L.14.6

CHAPTER 35 HUMAN IMMUNE SYSTEM STANDARDS:SC.912.L.14.52 & SC.912.L.14.6 SECTION 1 - Infectious Disease 1.Identify the causes of infectious disease. 2.Explain how infectious diseases are spread. Causes

Department of Parasitology, Faculty of Medicine, Chiang Mai University, Chiang Mai; 2

SOUTHEAST ASIAN J TROP MED PUBLIC HEALTH IDENTIFICATION OF HLA-A24 RESTRICTED PRE-ERYTHROCYTIC STAGE SPECIFIC T-CELL EPITOPES USING PLASMODIUM FALCIPARUM SYNTHETIC PEPTIDES: A PRELIMINARY STUDY Pongsri

Principles of Vaccination

Immunology and Vaccine-Preventable Diseases Immunology is a complicated subject, and a detailed discussion of it is beyond the scope of this text. However, an understanding of the basic function of the

BioMmune Technologies Inc. Corporate Presentation 2015

BioMmune Technologies Inc Corporate Presentation 2015 * Harnessing the body s own immune system to fight cancer & other autoimmune diseases BioMmune Technologies Inc. (IMU) ABOUT A public biopharmaceutical

Immunity and how vaccines work

1 Introduction Immunity is the ability of the human body to protect itself from infectious disease. The defence mechanisms of the body are complex and include innate (non-specific, non-adaptive) mechanisms

Vaccines to address the needs of the of 21 st century society

Vaccines to address the needs of the of 21 st century society Rino Rappuoli Viruses, the invisible enemy, Sixth world conference on the Future of Science Venezia, September 20, 2010 Vaccine in the 20 th

Third Meeting of Developing Countries' Vaccine Regulators Network Regulatory Forum on HIV Vaccines November 17-18, 2005

Third Meeting of Developing Countries' Vaccine Regulators Network Regulatory Forum on HIV Vaccines November 17-18, 2005 HIV Vaccines in Asia:- Welcome Address given by WR Thailand. Introduction of attendants,

Adjuvant Development for IPV. Martin Friede Ph.D. Initiative for Vaccine Research

Adjuvant Development for IPV Martin Friede Ph.D. Initiative for Vaccine Research Role of adjuvants in vaccine development Enable subunit antigens to induce protective immune response Achieve protective

2) Macrophages function to engulf and present antigen to other immune cells.

Immunology The immune system has specificity and memory. It specifically recognizes different antigens and has memory for these same antigens the next time they are encountered. The Cellular Components

What Shots Do I Need? Stan Houston MD DTM&H FRCPC Department of Medicine & School of Public Health Consultant, Travellers Health Service

What Shots Do I Need? Stan Houston MD DTM&H FRCPC Department of Medicine & School of Public Health Consultant, Travellers Health Service Faculty /Presenter Disclosure Faculty: Stan Houston Relationships

BACKGROUNDER NEW GRANTS TO ACCELERATE HIV VACCINE DEVELOPMENT

BACKGROUNDER NEW GRANTS TO ACCELERATE HIV VACCINE DEVELOPMENT The Bill & Melinda Gates Foundation has provided 16 grants totaling $287 million over five years to establish an international network of HIV

Multiple Choice Questions

C hapter 13 WHY DO WE FALL ILL Multiple Choice Questions 1. Which one of the following is not a viral disease? (a) Dengue (b) AIDS (c) Typhoid (d) Influenza 2. Which one of the following is not a bacterial

Monash Antibody Technologies Facility

Monash Antibody Technologies Facility The Monash Antibody Technologies Facility: A high throughput monoclonal antibody production platform for phospho-kinomics Tecan Symposium Zürich September 2007 What

The Rapidly Evolving Regulatory Landscape in Africa

The Rapidly Evolving Regulatory Landscape in Africa B. Dicky Akanmori Regional Advisor, Vaccine Regulation Immunization, Vaccines & Emergencies Cluster What has changed? Prime targets for vaccine development

Chapter 43: The Immune System

Name Period Our students consider this chapter to be a particularly challenging and important one. Expect to work your way slowly through the first three concepts. Take particular care with Concepts 43.2

Detection of T-cell T and their application to vaccine design

QuickTime and a TIFF (Uncompressed) decompressor are needed to see this picture Detection of T-cell T epitopes and their application to vaccine design EpiVax Inc. 16 Bassett Street Providence Rhode Island

III III a IIOI OlD III OlD IIO 1101 010 III DID III 100 III0 II uii IIi

III III a IIOI OlD III OlD IIO 1101 010 III DID III 100 III0 II uii IIi US oi ^^_._.,o.i ^,) United States (12) Patent Application Publication Buyse et al. (43) Pub. Date: Oct. 28, (54) HPV POLYEPITOPE

Defining Response in Prostate Cancer Immunotherapy. Lawrence Fong! University of California, San Francisco!

Defining Response in Prostate Cancer Immunotherapy Lawrence Fong! University of California, San Francisco! U!C! S!F! Prostate Cancer Clinical States Pre-chemotherapy Post-chemotherapy (Scher et al, JCO

The Immune System and Disease

Chapter 40 The Immune System and Disease Section 40 1 Infectious Disease (pages 1029 1033) This section describes the causes of disease and explains how infectious diseases are transmitted Introduction

Hepatitis C Vaccines: Are we making progress?

Hepatitis C Vaccines: Are we making progress? Second International Hepatitis Cure and Eradication Meeting. Vancouver November, 2015 Objectives: Review the need for a preventive vaccine in 2015. Identify

Status of Vaccine Research and Development of Vaccines for RSV Prepared for WHO PD-VAC Date submitted: June 30, 2014

Status of Vaccine Research and Development of Vaccines for RSV Prepared for WHO PD-VAC Date submitted: June 30, 2014 I. About the Disease and Pathogen Basic information on pathogen, including transmission,

Vaccine Manufacturing Facilities of the Future. Howard L. Levine, Ph.D. Vaccines Europe London, England December 1 2, 2010

Vaccine Manufacturing Facilities of the Future Howard L. Levine, Ph.D. Vaccines Europe London, England December 1 2, 2010 Challenges in the Production of Vaccines Different technology platforms make it

Nieuws? 24 people who had been in close contact with infected family members but had never become ill. In 11 people, the researchers found antibodies to the Ebola virus, indicating they had been infected.

Genetic Engineering and Biotechnology

1 So, what is biotechnology?? The use of living organisms to carry out defined chemical processes for industrial or commercial application. The office of Technology Assessment of the U.S. Congress defines

T cell Epitope Prediction

Institute for Immunology and Informatics T cell Epitope Prediction EpiMatrix Eric Gustafson January 6, 2011 Overview Gathering raw data Popular sources Data Management Conservation Analysis Multiple Alignments

UCSF Communicable Disease Surveillance and Vaccination Policy

Office of Origin: Occupational Health Program I. PURPOSE To provide a sustainable, healthy and safe working environment for UCSF research laboratory staff, and animal research care staff and to prevent

2012-Annual Report. Annual Report 2012 - Institut Pasteur

2012-Annual Report Name of the Department: Name of the Structure: Direction Médicale Pôle Intégré de Recherche Clinique (PIRC) Secondary Affiliation: - Head of the laboratory: Dr Cécile Delval, Cecile.delval@pasteur.fr

Protein Expression and Analysis. Vijay Yajnik, MD, PhD GI Unit MGH

Protein Expression and Analysis Vijay Yajnik, MD, PhD GI Unit MGH Identify your needs Antigen production Biochemical studies Cell Biology Protein interaction studies including proteomics Structural studies

HuCAL Custom Monoclonal Antibodies

HuCAL Custom Monoclonal HuCAL Custom Monoclonal Antibodies Highly Specific, Recombinant Antibodies in 8 Weeks Highly Specific Monoclonal Antibodies in Just 8 Weeks HuCAL PLATINUM (Human Combinatorial Antibody

Guidelines for TB Blood Testing. Minnesota Department of Health TB Prevention and Control Program June 2011

Guidelines for TB Blood Testing Minnesota Department of Health TB Prevention and Control Program June 2011 Outline Interferon-Gamma Release Assays aka TB blood tests 1. What are they? 2. What are the current

Chapter 3. Immunity and how vaccines work

Chapter 3 Immunity and how vaccines work 3.1 Objectives: To understand and describe the immune system and how vaccines produce immunity To understand the differences between Passive and Active immunity

specific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins

Adaptive Immunity Chapter 17: Adaptive (specific) Immunity Bio 139 Dr. Amy Rogers Host defenses that are specific to a particular infectious agent Can be innate or genetic for humans as a group: most microbes

Valneva Reports Preliminary FY 2013 Revenues of EUR 36.0m and Cash Position of EUR 40.2m at End of 2013

Valneva Reports Preliminary FY 2013 Revenues of EUR 36.0m and Cash Position of EUR 40.2m at End of 2013 Revenue Ahead of Guidance and Cash Target Met in First year Following Merger Total revenues and grants

INSTITUTO BUTANTAN. 800.000 m 2

NIT do INSTITUTO BUTANTAN 1901 Established to produce serum against the bubonic plague Vital Brazil, first director, investigated antivenoms against snake bites 800.000 m 2 INSTITUTO BUTANTAN 23 scientific

PX Therapeutics : the partner for early stage biotherapeutics development Biotuesday, May 5 2009

PX Therapeutics : the partner for early stage biotherapeutics development Biotuesday, May 5 2009 Christelle Dagoneau, PhD Business Development Director Company Profile Protein expert incorporated in 2000

Infectious Diseases. The programme aims to share the Israeli experience in the identification, prevention and treatment of infectious diseases.

Management International and Control Programme: of HIV/AIDS and Infectious Diseases Introduction Infectious diseases continue to significantly threaten the lives of many, despite the development of vaccinations,

Vaccine Development for Developing Countries Regulatory Approach in the European Union

Vaccine Development for Developing Countries Regulatory Approach in the European Union Dr. Manfred G. Haase, Langen, Germany ECI Vaccine Technology II, June 1-6, 2008, Albufeira, Portugal 1 Regulation

Genetics Lecture Notes 7.03 2005. Lectures 1 2

Genetics Lecture Notes 7.03 2005 Lectures 1 2 Lecture 1 We will begin this course with the question: What is a gene? This question will take us four lectures to answer because there are actually several

Principles of Vaccination

Immunology and Vaccine-Preventable Diseases Immunology is a complicated subject, and a detailed discussion of it is beyond the scope of this text. However, an understanding of the basic function of the

ATTACHMENT 2. New Jersey Department of Health Tuberculosis Program FREQUENTLY ASKED QUESTIONS

ATTACHMENT 2 New Jersey Department of Health Tuberculosis Program FREQUENTLY ASKED QUESTIONS 1. QUESTION Is it required to submit the Annual Report of TB Testing in Schools Form (TB-57) to the New Jersey

Ambulance Service Patient Care and Transportation Standards

Ambulance Service Patient Care and Transportation Standards Patient Care A. General Each operator and each emergency medical attendant and paramedic employed by the operator, shall: (a) Ensure that each

Protein Protein Interactions (PPI) APID (Agile Protein Interaction DataAnalyzer)

APID (Agile Protein Interaction DataAnalyzer) 23 APID (Agile Protein Interaction DataAnalyzer) Integrates and unifies 7 DBs: BIND, DIP, HPRD, IntAct, MINT, BioGRID. Includes 51,873 proteins 241,204 interactions

Travel Vaccine Schedule

Travel Vaccine Schedule This table acts as a quick guide to vaccine schedules. The Summary of Product Characteristics should always be referred to for more detailed information. Vaccine Cholera Dukoral

Chapter 1 Summary basic cause of acquired immunodeficiency several years, it is too soon to tell what percent- syndrome

Chapter 1 Summary Chapter 1 Summary The basic cause of acquired immunodeficiency syndrome (AIDS) is almost certainly a newly discovered virus, human T-cell lymphotropic virus, type III, or HTLV-III. Researchers

NATIONAL DRUG POLICY ON MALARIA (2013)

203 - 2 - NATIONAL DRUG POLICY ON MALARIA (203) Preamble Malaria is one of the major public health problems of the country. Around.5 million laboratory confirmed cases of malaria are annually reported

IMPORTANT: PLEASE READ

PART III: CONSUMER INFORMATION combined hepatitis A (inactivated) and hepatitis B (recombinant) vaccine This leaflet is part III of a three-part "Product Monograph" published when was approved for sale

Vaccine-based mitigation of the 2014 Ebola Viral Disease (EVD) epidemic: Gap analysis and proposal for Norwegian initiatives

Vaccine-based mitigation of the 2014 Ebola Viral Disease (EVD) epidemic: Gap analysis and proposal for Norwegian initiatives Gunnstein Norheim, Fredrik Oftung, Sara Watle, Berit Sofie Wiklund, Dimitrios

Biologics Drug Discovery: Steps to producing an antibody drug candidate Frank Fan, M.D. Ph.D. Frank.fan@genscript.com

Biologics Drug Discovery: Steps to producing an antibody drug candidate Frank Fan, M.D. Ph.D. Frank.fan@genscript.com Director of Antibody & Protein Engineering About GenScript Gene Services Peptide Services

Antibody Function & Structure

Antibody Function & Structure Specifically bind to antigens in both the recognition phase (cellular receptors) and during the effector phase (synthesis and secretion) of humoral immunity Serology: the

Immunity Unit Test Z

Immunity Unit Test Z Name MB Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Which of the pathogens in Figure 31.1 cause disease by taking over healthy

Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO

Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO Statistically significant difference in progression-free survival continues to be seen in non-squamous

How to construct transgenic mice

How to construct transgenic mice Sandra Beer-Hammer Autumn School 2012 Bad Schandau Pharmakologie und Experimentelle Therapie (APET) Overview History Generation of embryonic stem (ES) cell lines Generation

Chickenpox and Shingles Vaccines

Chickenpox and Shingles Vaccines The chicken pox/shingles connection DISCLAIMER: The following is not intended as advice on whether or not to receive a chicken pox, shingles, or any other vaccine. The

USE OF GIOVANNI SYSTEM IN PUBLIC HEALTH APPLICATION

USE OF GIOVANNI SYSTEM IN PUBLIC HEALTH APPLICATION 2 0 1 2 G R EG O RY G. L E P TO U K H O N L I N E G I OVA N N I WO R K S H O P SEPTEMBER 25, 2012 Radina P. Soebiyanto 1,2 Richard Kiang 2 1 G o d d

10. T and B cells are types of a. endocrine cells. c. lymphocytes. b. platelets. d. complement cells.

Virus and Immune System Review Directions: Write your answers on a separate piece of paper. 1. Why does a cut in the skin threaten the body s nonspecific defenses against disease? a. If a cut bleeds, disease-fighting

MOSAIC HIV Prophylactic Vaccine

MOSAIC HIV Prophylactic Vaccine Overview Development Program Hanneke Schuitemaker Head Viral Vaccines Discovery & Translational Medicine March 16, 2015 Melinda, Goddess of Healing Melinda s artwork reflects

Compiled and/or written by Amy B. Vento and David R. Gillum

Fact Sheet Describing Recombinant DNA and Elements Utilizing Recombinant DNA Such as Plasmids and Viral Vectors, and the Application of Recombinant DNA Techniques in Molecular Biology Compiled and/or written

III III a IIOI OlD III OII OlD IIO IIO 1101 0II II 0II lulu II uii IIi

(19) United States III III a IIOI OlD III OII OlD IIO IIO 1101 0II II 0II lulu II uii IIi US 20110002916A1 (12) Patent Application Publication (10) Pub. No.: US 2011/0002916 Al Druilhe et al. (43) Pub.

GenScript Antibody Services

GenScript Antibody Services Scientific experts, innovative technologies, proven performance We specialize in custom antibody production to empower your research Custom Polyclonal Antibody Production Custom

Catching the Flu: A Photo Essay

May 2006 Catching the Flu: A Photo Essay As it tests a new way of making vaccines, TechnoVax is targeting the deadly 1918 flu virus. By Stephan Herrera (MIT Technology Review) Jose Galarza is the CEO of

KMS-Specialist & Customized Biosimilar Service

KMS-Specialist & Customized Biosimilar Service 1. Polyclonal Antibody Development Service KMS offering a variety of Polyclonal Antibody Services to fit your research and production needs. we develop polyclonal

Guidelines for Vaccinating Pregnant Women

Guidelines for Vaccinating Pregnant Women U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Disease Control & Prevention Guidelines for Vaccinating Pregnant Women from Recommendations of the Advisory

Enveloped Virus Like Particles: Third-generation VLPs for the Development of a Broadly Neutralizing Hepatitis C Vaccine

Enveloped Virus Like Particles: Third-generation VLPs for the Development of a Broadly Neutralizing Hepatitis C Vaccine World Vaccine Congress Asia June 2015 Forward-Looking Statement Disclaimer This presentation

Analysis of the adaptive immune response to West Nile virus

Analysis of the adaptive immune response to West Nile virus Jonathan Bramson (PI) Robin Parsons Alina Lelic Galina Denisova Lesley Latham Carole Evelegh Dmitri Denisov Strategy for characterizing T cell

Institute for OneWorld Health

Institute for OneWorld Health a nonprofit pharmaceutical company Oxymoron no more: nonprofits can deliver medicines for the poor of the world January 10, 2005 Victoria Hale, PhD CEO, OneWorld Health The

An Overview of Cells and Cell Research

An Overview of Cells and Cell Research 1 An Overview of Cells and Cell Research Chapter Outline Model Species and Cell types Cell components Tools of Cell Biology Model Species E. Coli: simplest organism

The role of IBV proteins in protection: cellular immune responses. COST meeting WG2 + WG3 Budapest, Hungary, 2015

The role of IBV proteins in protection: cellular immune responses COST meeting WG2 + WG3 Budapest, Hungary, 2015 1 Presentation include: Laboratory results Literature summary Role of T cells in response

Advances in Treatment of Malignant Pleural Mesothelioma: A Reason for Hope

Advances in Treatment of Malignant Pleural Mesothelioma: A Reason for Hope Daniel H. Sterman, M.D. Associate Professor of Medicine and Surgery Co-Director, PENN Mesothelioma and Pleural Program University

PAVE 2016 Internships

PAVE 2016 Internships I. World Health Organization, Immunization, Vaccines, and Biological Division (WHO IVB) 1. Development of surveillance standards for typhoid and other invasive salmonellosis 2. Cost

3 months 1.5 months 1.5 months. 1 month

Rabbit monoclonal antibody (Mab) is secreted by the plasma B-cell of the rabbit. Traditional generation of rabbit Mab relies on a rabbit myeloma for B- cell fusion (